Loading
A phase 3 trial testing Clifutinib in acute myeloid leukaemia, now recruiting.
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML is a phase 3 interventional study registered as NCT05586074, led by Sunshine Lake Pharma, and recruiting on the registry. Official title: HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukaemia: a Multicenter, Open-label, Randomised Phase 3 Trial. Planned enrolment is 324 participants (estimated). The study started in 2023-03-03 and primary completion is expected in 2027-11-30. No results have been posted on ClinicalTrials.gov.
Shares Clifutinib, Sunshine Lake Pharma (HEC), Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.